Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Some index funds distribute fewer capital gains than others, which can reduce tax surprises and improve after-tax performance over time.
28,126 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Base58 Labs unveils BASIS 2026 blueprint, aiming to redefine institutional access to BTC, ETH, SOL, and PAXG through ...
After Microsoft's pullback, savvy investors look for durable megacap ideas. This guide highlights three top megacap s...
Is Nebius the nebius next amazon? This article digs into Nebius's model, how it stacks up to Amazon, and what it woul...
Sumitomo Forestry has completed its $4.5 billion acquisition of Tri Pointe Homes, moving the combined group into the ...
With July 7 approaching, many investors wonder if SpaceX is a buy. This guide breaks down the key catalysts, risks, a...
Klarna has faced a sharp pullback this year, leaving investors wondering if the drop creates a buying opportunity. Th...
Netflix walked away from a blockbuster deal, but that decision opens two compelling paths for investors. This article...
CoreWeave's backlog booming has caught the eye of investors eyeing AI infrastructure. This piece breaks down whether ...
Veteran market commentator Jim Cramer signaled a shift to caution, saying funds are drying up for big tech deals. The...
In March 2026, investors weigh IMAX, SHARKNINJA, and SONOS as each pushes growth through screens, margins, and softwa...
When health scares strike, money decisions follow. This feature explores how penélope cruz says brain health reshapes...